Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary cancer treatment modality, offering long-lasting responses and survival benefits for a substantial number of cancer patients. However, the response rates to ICIs vary significantly among individuals and cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Xianjing, Tian, Wentao, Wang, Ziqi, Zhang, Jing, Zhou, Rongrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249258/
https://www.ncbi.nlm.nih.gov/pubmed/37291608
http://dx.doi.org/10.1186/s12943-023-01800-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249258/
https://www.ncbi.nlm.nih.gov/pubmed/37291608
http://dx.doi.org/10.1186/s12943-023-01800-3

Ejemplares similares